Shelby Coates

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Emergency Department

Pain Management

Top Venues

Expert review of clinical pharmacology

The Journal of pharmacology and experimental therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Keti Bardhi, Shelby Coates, Gang Chen, Philip Lazarus
Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions. Pharmaceutics 16 (2) (2024)
Shelby Coates, Keti Bardhi, Philip Lazarus
Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions. Pharmaceutics 16 (3) (2024)
Shelby Coates, Keti Bardhi, Philip Lazarus
Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions. Pharmaceutics 16 (3) (2024)
Keti Bardhi, Shelby Coates, Gang Chen, Philip Lazarus
Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions. Pharmaceutics 16 (2) (2024)
Shelby Coates, Keti Bardhi, Philip Lazarus
Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions. Pharmaceutics 16 (3) (2024)
Shelby Coates, Keti Bardhi, Philip Lazarus
Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions. Pharmaceutics 16 (3) (2024)
Shelby Coates, Philip Lazarus
Hydrocodone, oxycodone, and morphine metabolism and drug-drug interactions. The Journal of pharmacology and experimental therapeutics (2023)
Keti Bardhi, Shelby Coates, Christy J W Watson, Philip Lazarus
Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy. Expert review of clinical pharmacology 15 (12) (2022)